Use of Pharmacogenomics to Guide Proton Pump Inhibitor Therapy in Clinical Practice

Harris, Dana M.; Stancampiano, Fernando; Burton, M. Caroline; Moyer, Ann M.; Schuh, Michael J.; Valery, Jose; Bi, Yan

doi:10.1007/s10620-020-06814-1

Cited by 12 publications

(13 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The CYP2C19 phenotypes tend to differ in relation to race. Loss of CYP2C19 *2, CYP2C19 *3, and other functiona, which are responsible for PM alleles, is mainly found in Asians 21 . CYP2C19 *2 has an allele frequency of 25–30% in Asians, about 15% in Europeans and Africans, and about 60% in Oceanians 9,18 .…”

Section: Discussionmentioning

confidence: 99%

“…Loss of CYP2C19 *2, CYP2C19 *3, and other functiona, which are responsible for PM alleles, is mainly found in Asians. 21 CYP2C19 *2 has an allele frequency of 25–30% in Asians, about 15% in Europeans and Africans, and about 60% in Oceanians. 9 , 18 The allele frequency of CYP2C19 *2 in our study is 31.1%, which is consistent with the 1000 Genomes and previous reports.…”

Section: Discussionmentioning

confidence: 99%

“…Our study protocol was approved by the Ethics Committee of Peking University First Hospital as the leading center (No. 2018 (21)) and the Ethics Committees of each bioequivalence clinical trials' hospital. Informed written consent was obtained from each subject.…”

Section: Study Design and Subjectsmentioning

confidence: 99%

See 2 more Smart Citations

Evaluation of the relationship between polymorphisms in CYP2C19 and the single‐dose pharmacokinetics of omeprazole in healthy Chinese volunteers: A multicenter study

Zhou

Xie

Zhang

et al. 2022

Clinical Translational Sci

View full text Add to dashboard Cite

The aim of this study was to evaluate the relationship between polymorphisms in CYP2C19 and the single-dose pharmacokinetics (PKs) of omeprazole in healthy Chinese volunteers. A 20 mg single dose of omeprazole (Losec) enteric-coated capsules or tablets was orally administered to 656 healthy subjects from eight subcenters. The polymorphic alleles of CYP2C19*2, *3, and *17 were determined by Sanger sequencing and Agena mass array. Plasma concentrations of omeprazole were determined by high-performance liquid-chromatography tandem mass spectrometry. PK parameters of area under the concentration versus time curve (AUC) 0-t , AUC from zero to infinity (AUC 0-∞ ), maximum plasma concentration (C max ), and terminal half-life (t 1/2 ) were significantly influenced by CYP2C19 phenotype (all p < 0.001) and diplotype (all p < 0.001), and the same results were obtained in the subgroup analysis of the effects of diet and dosage form.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of the relationship between polymorphisms in CYP2C19 and the single‐dose pharmacokinetics of omeprazole in healthy Chinese volunteers: A multicenter study

Zhou

Xie

Zhang

et al. 2022

Clinical Translational Sci

View full text Add to dashboard Cite

show abstract

“…Следует заметить, что сейчас доминирует точка зрения о том, что полиморфизм CYP2C19 активно влияет на результаты лечения эрозивного эзофагита и эрадикацию Helicobacter pylori. В частности, ответ на лечение эрозивного эзофагита и эрадикацию Helicobacter pylori является более высоким у медленных метаболизаторов в сравнении с быстрыми и нормальными метаболизаторами CYP2C19 [1,2]. В японском метаанализе было проанализировано 19 исследований с продолжительностью терапии ГЭРБ 8 нед.…”

Section: Discussionunclassified

“…В зависимости от наличия разных аллелей генов изофермента CYP2C19 сейчас принято выделять 5 основных фенотипов, характеризующихся различной скоростью метаболизма ИПП, что влияет на концентрацию препаратов в организме и, соответственно, изменяет их клиническую эффективность [1]. В современных систематических обзорах высказывается точка зрения о действии полиморфизма CYP2C19 на результаты лечения язвенной болезни, эрозивного эзофагита и эрадикации Helicobacter pylori [2]. В этой связи мы предприняли собственное исследование и проанализировали данные литературы в этом направлении.…”

Section: Introductionunclassified

The influence of CYP2C19 polymorphism on the effectiveness of the treatment of acid-dependent diseases

et al. 2022

View full text Add to dashboard Cite

Introduction. In modern systematic reviews, there is a point of view that CYP2C19 polymorphism affects the results of treatment of peptic ulcer, erosive esophagitis and eradication of Helicobacter pylori.Оbjective. To evaluate the effect of CYP2C19 polymorphism on the effectiveness of treatment with rabeprazole at a dose of 20 mg once a day in patients with GERD during 2 and 4 weeks of treatment.Materials and methods. In total, the study included 75 patients with GERD (36 men and 39 women, mean age 41.7 ± 1.5 years). A clinical examination with the completion of standard questionnaires took place during three visits: before the start of treatment, after 2 and after 4 weeks of therapy. Esophagogastroduodenoscopy was performed in all patients before treatment and in patients with esophagitis after 4 weeks of therapy. All patients received rabeprazole at a dose of 20 mg once a day. Genotyping of single nucleotide polymorphisms of CYP2C19 metabolizer genes was carried out by real-time polymerase chain reaction. Ultrarapid, rapid, normal, intermediate and poor CYP2C19 metabolizers have been isolated.Results. Of the 75 patients examined, 8.0% of patients were ultrarapid metabolizers, 30.7% of people were rapid, 49.3% of individuals were normal, 10.7% of persons were intermediate, and 1.3% of patients were poor CYP2C19 metabolizers. Response after 4 weeks of treatment with rabeprazole 20 mg once daily was 94.4% for NERD and 90.5% for erosive esophagitis. In ultrarapid and rapid metabolizers of CYP2C19, a complete response to rabeprazole therapy was registered in 81.3% of NERD patients and in 84.6% of patients with erosive esophagitis.Conclusion. Based on the results of the study, we obtained high efficacy of Razo® at a dose of 20 mg 1 time per day for the treatment of GERD in a group of patients with a predominance of rapid and normal metabolizers of CYP2C19.

show abstract

Impact of medication dosage on Helicobacter pylori eradication rates among pediatric patients

Andrews,

Herzlinger,

Riaz

et al. 2024

J. pediatr. gastroenterol. nutr.

View full text Add to dashboard Cite

ObjectivesHelicobacter pylori rates of eradication to common first‐line regimens continue to decline globally. Prescription of the appropriate medication dosage is an important consideration, particularly in the pediatric population due to medication weight‐based dosing. Limited data is available on the impact of guideline‐recommended weight‐based dosing on the successful eradication of H. pylori in children.MethodsRetrospective study of patients with histologic evidence of H. pylori from two pediatric tertiary care centers in New England. We excluded patients who were not treated or those missing eradication data. We compared the eradication rates of patients prescribed recommended weight‐based dosages, duration, and frequency of treatment with those who were not.ResultsOne hundred forty‐four patients were included. The overall eradication rate was 73.6% (106/144). All treatment regimens were properly prescribed for 14 days. There was a high rate of improper weight‐based dosing: proton pump inhibitor (PPI) 31.2% (45/144), amoxicillin 31.7% (39/123), metronidazole (MET) 19.4% (12/62), clarithromycin (CLA) 23.9% (22/70), tetracycline 50% (6/12), bismuth 26.1% (6/23). When PPIs were properly weight‐dosed, there was a 78.8% eradication rate that dropped to 62.2% with suboptimal dosing (p = 0.036, OR: 2.26, CI: 1.04−4.87). When amoxicillin was properly weight‐dosed, successful eradication was achieved in 81% versus only 53.8% when improperly dosed (p = 0.002; OR: 3.64, CI: 1.58−8.37). There was no statistically significant impact on eradication rates with improper weight‐based dosing of MET, CLA, tetracycline, or bismuth.ConclusionProper weight‐based dosing of amoxicillin and PPI is important for the successful eradication of H. pylori among children in the New England area.

show abstract

Use of Pharmacogenomics to Guide Proton Pump Inhibitor Therapy in Clinical Practice

Cited by 12 publications

References 32 publications

Evaluation of the relationship between polymorphisms in CYP2C19 and the single‐dose pharmacokinetics of omeprazole in healthy Chinese volunteers: A multicenter study

Evaluation of the relationship between polymorphisms in CYP2C19 and the single‐dose pharmacokinetics of omeprazole in healthy Chinese volunteers: A multicenter study

The influence of CYP2C19 polymorphism on the effectiveness of the treatment of acid-dependent diseases

Impact of medication dosage on Helicobacter pylori eradication rates among pediatric patients

Contact Info

Product

Resources

About